MEA Pemphigus Vulgaris Market - Industry Trends and Forecast to 2030

TABLE OF CONTENTS

1 INTRODUCTION 31

• 1.1 OBJECTIVES OF THE STUDY 31
• 1.2 MARKET DEFINITION 31
• 1.3 OVERVIEW 31
• 1.4 CURRENCY AND PRICING 33
• 1.5 LIMITATIONS 33
• 1.6 MARKETS COVERED 33

2 MARKET SEGMENTATION 36

• 2.1 MARKETS COVERED 36
• 2.2 GEOGRAPHICAL SCOPE 37
• 2.3 YEARS CONSIDERED FOR THE STUDY 38
• 2.4 DBMR TRIPOD DATA VALIDATION MODEL 39
• 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 42
• 2.6 MULTIVARIATE MODELLING 43
• 2.7 MARKET APPLICATION COVERAGE GRID 44
• 2.8 PRODUCT LIFELINE CURVE 45
• 2.9 DBMR MARKET POSITION GRID 46
• 2.10 VENDOR SHARE ANALYSIS 47
• 2.11 SECONDARY SOURCES 48
• 2.12 ASSUMPTIONS 48

3 EXECUTIVE SUMMARY 49

4 PREMIUM INSIGHTS 51

• 4.1 PESTEL ANALYSIS 52
• 4.2 PORTER FIVE FORCES 53
• 4.3 PATENT ANALYSIS 54
• 4.4 PATIENT FLOW DIAGRAM 55
• 4.5 KEY PRICING STRATEGIES 56
• 4.6 FUTURE THERAPIES 57
• 4.7 KEY PATIENT ENROLLMENT STRATEGIES 58

5 PIPELINE ANALYSIS 59

6 EPIDEMIOLOGY 60

7 INDUSTRY INSIGHTS 61

8 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: REGULATIONS 62

9 MARKET OVERVIEW 65

• 9.1 DRIVERS 67
  • 9.1.1 EMERGING TREATMENT OPTIONS FOR PEMPHIGUS VULGARIS 67
  • 9.1.2 GROWING SUPPORT OF NGOS FOR THE AFFECTED PATIENTS 67
  • 9.1.3 AWARENESS REGARDING THE DISEASE 68
• 9.2 RESTRAINTS 68
  • 9.2.1 STRICT REGULATORY GUIDELINES 68
  • 9.2.2 HIGH TREATMENT COSTS 68
• 9.3 OPPORTUNITIES 69
  • 9.3.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 69
  • 9.3.2 INCREASING HEALTHCARE FACILITIES 69
  • 9.3.3 DIGITAL HEALTH TECHNOLOGIES FOR TREATMENT MANAGEMENT 70
• 9.4 CHALLENGES 70
  • 9.4.1 ADVERSE EFFECTS ASSOCIATED WITH MEDICATIONS 70
  • 9.4.2 REIMBURSEMENT AND COVERAGE POLICIES 71

10 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT 72

• 10.1 OVERVIEW 73
• 10.2 TREATMENT 76
  • 10.2.1 MEDICATIONS, BY TYPE 76
    • 10.2.1.1 CORTICOSTEROIDS 77
    • 10.2.1.2 STEROID- SPARING IMMUNOSUPPRESSANT DRUGS 77
      • 10.2.1.2.1 AZATHIOPRINE 78
      • 10.2.1.2.2 MYCOPHENALATE MOFETIL 78
      • 10.2.1.2.3 METHOTREXATE 78
      • 10.2.1.2.4 CYCLOPHOSPHAMIDE 78
      • 10.2.1.2.5 MIZORIBINE 78
      • 10.2.1.2.6 OTHERS 78
    • 10.2.1.3 ANTI- INFLAMMATORY AGENTS 78
      • 10.2.1.3.1 DIAMINODYPHENYL SULFONE 79
      • 10.2.1.3.2 TETRACYCLINE 79
      • 10.2.1.3.3 OTHERS 79
    • 10.2.1.4 BIOLOGICS 79
    • 10.2.1.5 INTRAVENOUS IMMUNOGLOBULIN 79
    • 10.2.1.6 ANTIBIOTICS 79
    • 10.2.1.7 ANTIFUNGALS 79
    • 10.2.1.8 ANTIVIRALS 79
    • 10.2.1.9 OTHER MEDICATIONS 79
  • 10.2.2 MEDICATIONS, BY ROUTE OF ADMINISTRATION 79
    • 10.2.2.1 ORAL 80
    • 10.2.2.2 TOPICAL 80
    • 10.2.2.3 PARENTERAL 80
    • 10.2.2.4 OTHERS 80
  • 10.2.3 MEDICATIONS, BY DRUG TYPE 80
    • 10.2.3.1 GENERIC 81
    • 10.2.3.2 BRANDED 81
• 10.3 DIAGNOSIS 81
  • 10.3.1 SKIN BIOPSY 82
  • 10.3.2 BLOOD TEST 82
  • 10.3.3 ENDOSCOPY 82

11 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE 83

• 11.1 OVERVIEW 84
• 11.2 ADULTS 87
• 11.3 GERIATRIC 88
• 11.4 PEDIATRIC 89

12 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET, BY END USER 90

• 12.1 OVERVIEW 91
• 12.2 HOSPITALS 94
• 12.3 SPECIALTY CLINICS 94
• 12.4 RESEARCH INSTITUTES 95
• 12.5 OTHERS 96

13 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL 97

• 13.1 OVERVIEW 98
• 13.2 HOSPITALS PHARMACY 101
• 13.3 RETAIL PHARMACY 101
• 13.4 ONLINE PHARMACY 102

14 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET, BY REGION 103

• 14.1 MIDDLE EAST AND AFRICA 104
  • 14.1.1 SAUDI ARABIA 112
  • 14.1.2 EGYPT 116
  • 14.1.3 U.A.E. 120
  • 14.1.4 SOUTH AFRICA 124
  • 14.1.5 ISRAEL 128
  • 14.1.6 REST OF MIDDLE EAST AND AFRICA 131

15 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET, COMPANY LANDSCAPE 132

• 15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 132

16 SWOT ANALYSIS 133

17 COMPANY PROFILE 134

• 17.1 ABBVIE INC. 134
  • 17.1.1 COMPANY SNAPSHOT 134
  • 17.1.2 REVENUE ANALYSIS 134
  • 17.1.3 COMPANY SHARE ANALYSIS 135
  • 17.1.4 PRODUCT PORTFOLIO 135
  • 17.1.5 RECENT DEVELOPMENTS 136
• 17.2 MERCK & CO., INC., 137
  • 17.2.1 COMPANY SNAPSHOT 137
  • 17.2.2 REVENUE ANALYSIS 137
  • 17.2.3 COMPANY SHARE ANALYSIS 138
  • 17.2.4 PRODUCT PORTFOLIO 138
  • 17.2.5 RECENT DEVELOPMENT 138
• 17.3 SANOFI 139
  • 17.3.1 COMPANY SNAPSHOT 139
  • 17.3.2 REVENUE ANALYSIS 139
  • 17.3.3 COMPANY SHARE ANALYSIS 140
  • 17.3.4 PRODUCT PORTFOLIO 140
  • 17.3.5 RECENT DEVELOPMENT 140
• 17.4 REGENERON PHARMACEUTICALS INC. 141
  • 17.4.1 COMPANY SNAPSHOT 141
  • 17.4.2 REVENUE ANALYSIS 141
  • 17.4.3 COMPANY SHARE ANALYSIS 142
  • 17.4.4 PRODUCT PORTFOLIO 142
  • 17.4.5 RECENT DEVELOPMENT 142
• 17.5 NOVARTIS AG 143
  • 17.5.1 COMPANY SNAPSHOT 143
  • 17.5.2 REVENUE ANALYSIS 143
  • 17.5.3 COMPANY SHARE ANALYSIS 144
  • 17.5.4 PRODUCT PORTFOLIO 144
  • 17.5.5 RECENT DEVELOPMENT 144
• 17.6 AMGEN INC. 145
  • 17.6.1 COMPANY SNAPSHOT 145
  • 17.6.2 REVENUE ANALYSIS 145
  • 17.6.3 PRODUCT PORTFOLIO 146
  • 17.6.4 RECENT DEVELOPMENTS 146
• 17.7 ASTRAZENECA 147
  • 17.7.1 COMPANY SNAPSHOT 147
  • 17.7.2 REVENUE ANALYSIS 147
  • 17.7.3 COMPANY SHARE ANALYSIS 148
  • 17.7.4 PRODUCT PORTFOLIO 148
  • 17.7.5 RECENT DEVELOPMENTS 149
• 17.8 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 150
  • 17.8.1 COMPANY SNAPSHOT 150
  • 17.8.2 REVENUE ANALYSIS 150
  • 17.8.3 PRODUCT PORTFOLIO 151
  • 17.8.4 RECENT DEVELOPMENT 151
• 17.9 CELLTRION HEALTHCARE CO., LTD 152
  • 17.9.1 COMPANY SNAPSHOT 152
  • 17.9.2 REVENUE ANALYSIS 152
  • 17.9.3 PRODUCT PORTFOLIO 153
  • 17.9.4 RECENT DEVELOPMENTS 153
• 17.10 F. HOFFMANN- LA ROCHE LTD. 154
  • 17.10.1 COMPANY SNAPSHOT 154
  • 17.10.2 REVENUE ANALYSIS 154
  • 17.10.3 PRODUCT PORTFOLIO 155
  • 17.10.4 RECENT DEVELOPMENT 155
• 17.11 FRESENIUS KABI AG 156
  • 17.11.1 COMPANY SNAPSHOT 156
  • 17.11.2 REVENUE ANALYSIS 156
  • 17.11.3 PRODUCT PORTFOLIO 157
  • 17.11.4 RECENT DEVELOPMENT 157
• 17.12 GSK PLC 158
  • 17.12.1 COMPANY SNAPSHOT 158
  • 17.12.2 REVENUE ANALYSIS 158
  • 17.12.3 PRODUCT PORTFOLIO 159
  • 17.12.4 RECENT DEVELOPMENT 159
• 17.13 JOHNSON & JOHNSON SERVICES, INC. 160
  • 17.13.1 COMPANY SNAPSHOT 160
  • 17.13.2 REVENUE ANALYSIS 160
  • 17.13.3 COMPANY SHARE ANALYSIS 161
  • 17.13.4 PRODUCT PORTFOLIO 161
  • 17.13.5 RECENT DEVELOPMENT 161
• 17.14 LILLY 162
  • 17.14.1 COMPANY SNAPSHOT 162
  • 17.14.2 REVENUE ANALYSIS 162
  • 17.14.3 PRODUCT PORTFOLIO 163
  • 17.14.4 RECENT DEVELOPMENT 163
• 17.15 PFIZER INC. 164
  • 17.15.1 COMPANY SNAPSHOT 164
  • 17.15.2 REVENUE ANALYSIS 164
  • 17.15.3 PRODUCT PORTFOLIO 165
  • 17.15.4 RECENT DEVELOPMENT 165
• 17.16 RAKSHIT DRUGS PVT. LTD 166
  • 17.16.1 COMPANY SNAPSHOT 166
  • 17.16.2 PRODUCT PORTFOLIO 166
  • 17.16.3 RECENT DEVELOPMENT 166
• 17.17 TEVA PHARMACEUTICAL INDUSTRIES LTD 167
  • 17.17.1 COMPANY SNAPSHOT 167
  • 17.17.2 REVENUE ANALYSIS 167
  • 17.17.3 PRODUCT PORTFOLIO 168
  • 17.17.4 RECENT DEVELOPMENT 168
• 17.18 ZYDUS GROUP 169
  • 17.18.1 COMPANY SNAPSHOT 169
  • 17.18.2 REVENUE ANALYSIS 169
  • 17.18.3 PRODUCT PORTFOLIO 170
  • 17.18.4 RECENT DEVELOPMENT 170

18 QUESTIONNAIRE 171

19 RELATED REPORTS 173

LIST OF TABLES

• TABLE 1 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET, PATENT ANALYSIS 40
• TABLE 2 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET, PIPELINE ANALYSIS 45
• TABLE 3 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 61
• TABLE 4 MIDDLE EAST & AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 62
• TABLE 5 MIDDLE EAST & AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 63
• TABLE 6 MIDDLE EAST & AFRICA STEROID- SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 63
• TABLE 7 MIDDLE EAST & AFRICA ANTI- INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 64
• TABLE 8 MIDDLE EAST & AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 66
• TABLE 9 MIDDLE EAST & AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 66
• TABLE 10 MIDDLE EAST & AFRICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 67
• TABLE 11 MIDDLE EAST & AFRICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 68
• TABLE 12 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 72
• TABLE 13 MIDDLE EAST & AFRICA ADULTS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 73
• TABLE 14 MIDDLE EAST & AFRICA GERIATRIC IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 74
• TABLE 15 MIDDLE EAST & AFRICA PEDIATRIC IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 75
• TABLE 16 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 79
• TABLE 17 MIDDLE EAST & AFRICA HOSPITALS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 80
• TABLE 18 MIDDLE EAST & AFRICA SPECIALTY CLINICS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 81
• TABLE 19 MIDDLE EAST & AFRICA RESEARCH INSTITUTES IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 81
• TABLE 20 MIDDLE EAST & AFRICA OTHERS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
• TABLE 21 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 86
• TABLE 22 MIDDLE EAST & AFRICA HOSPITALS PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 87
• TABLE 23 MIDDLE EAST & AFRICA RETAIL PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 88
• TABLE 24 MIDDLE EAST & AFRICA ONLINE PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 88
• TABLE 25 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 94
• TABLE 26 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 94
• TABLE 27 MIDDLE EAST AND AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 94
• TABLE 28 MIDDLE EAST AND AFRICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 95
• TABLE 29 MIDDLE EAST AND AFRICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 95
• TABLE 30 MIDDLE EAST AND AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 95
• TABLE 31 MIDDLE EAST AND AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 96
• TABLE 32 MIDDLE EAST AND AFRICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 96
• TABLE 33 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 96
• TABLE 34 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 97
• TABLE 35 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 97
• TABLE 36 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 98
• TABLE 37 SAUDI ARABIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 98
• TABLE 38 SAUDI ARABIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 99
• TABLE 39 SAUDI ARABIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 99
• TABLE 40 SAUDI ARABIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 99
• TABLE 41 SAUDI ARABIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 100
• TABLE 42 SAUDI ARABIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 100
• TABLE 43 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 100
• TABLE 44 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 101
• TABLE 45 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 101
• TABLE 46 EGYPT PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 102
• TABLE 47 EGYPT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 102
• TABLE 48 EGYPT STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 103
• TABLE 49 EGYPT ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 103
• TABLE 50 EGYPT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 103
• TABLE 51 EGYPT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 104
• TABLE 52 EGYPT DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 104
• TABLE 53 EGYPT PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 104
• TABLE 54 EGYPT PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 104
• TABLE 55 EGYPT PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 105
• TABLE 56 U.A.E. PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 106
• TABLE 57 U.A.E. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 106
• TABLE 58 U.A.E. STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 107
• TABLE 59 U.A.E. ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 107
• TABLE 60 U.A.E. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 107
• TABLE 61 U.A.E. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 108
• TABLE 62 U.A.E. DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 108
• TABLE 63 U.A.E. PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 108
• TABLE 64 U.A.E. PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 108
• TABLE 65 U.A.E. PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 109
• TABLE 66 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 110
• TABLE 67 SOUTH AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 110
• TABLE 68 SOUTH AFRICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 111
• TABLE 69 SOUTH AFRICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 111
• TABLE 70 SOUTH AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 111
• TABLE 71 SOUTH AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 112
• TABLE 72 SOUTH AFRICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 112
• TABLE 73 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 112
• TABLE 74 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 113
• TABLE 75 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 113
• TABLE 76 ISRAEL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 114
• TABLE 77 ISRAEL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 114
• TABLE 78 ISRAEL STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 114
• TABLE 79 ISRAEL ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 115
• TABLE 80 ISRAEL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 115
• TABLE 81 ISRAEL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 115
• TABLE 82 ISRAEL DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 115
• TABLE 83 ISRAEL PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 116
• TABLE 84 ISRAEL PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 116
• TABLE 85 ISRAEL PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 116
• TABLE 86 REST OF MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 117

LIST OF FIGURES

• FIGURE 1 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: SEGMENTATION 21
• FIGURE 2 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: DATA TRIANGULATION 24
• FIGURE 3 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: DROC ANALYSIS 25
• FIGURE 4 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS 26
• FIGURE 5 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: COMPANY RESEARCH ANALYSIS 26
• FIGURE 6 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: INTERVIEW DEMOGRAPHICS 27
• FIGURE 7 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: MARKET APPLICATION COVERAGE GRID 29
• FIGURE 8 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: DBMR MARKET POSITION GRID 31
• FIGURE 9 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: VENDOR SHARE ANALYSIS 32
• FIGURE 10 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: SEGMENTATION 35
• FIGURE 11 THE EMERGING TREATMENT OPTIONS FOR THE PEMPHIGUS VULGARISIS EXPECTED TO DRIVE THE GROWTH OF THE MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET FROM 2023 TO 2030 36
• FIGURE 12 THE DIAGNOSIS AND TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET IN 2023 AND 2030 36
• FIGURE 13 PATIENT FLOW DESCRIPTION OF PEMPHIGUS VULGARIS:- 40
• FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET 51
• FIGURE 15 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, 2022 58
• FIGURE 16 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, 2023-2030 (USD MILLION) 59
• FIGURE 17 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, CAGR (2023-2030) 59
• FIGURE 18 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, LIFELINE CURVE 60
• FIGURE 19 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, 2022 69
• FIGURE 20 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, 2023-2030 (USD MILLION) 70
• FIGURE 21 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, CAGR (2023-2030) 70
• FIGURE 22 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, LIFELINE CURVE 71
• FIGURE 23 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: BY END USER, 2022 76
• FIGURE 24 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: BY END USER, 2023-2030 (USD MILLION) 77
• FIGURE 25 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: BY END USER, CAGR (2023-2030) 77
• FIGURE 26 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: BY END USER, LIFELINE CURVE 78
• FIGURE 27 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, 2022 83
• FIGURE 28 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 84
• FIGURE 29 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 84
• FIGURE 30 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 85
• FIGURE 31 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022) 90
• FIGURE 32 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022) 91
• FIGURE 33 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2023 & 2030) 91
• FIGURE 34 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022 & 2030) 92
• FIGURE 35 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET: DIAGNOSIS AND TREATMENT (2023-2030) 92
• FIGURE 36 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2022 (%) 117